| Literature DB >> 25539983 |
Dorcas M Kamuya1,2, Vicki Marsh3,4, Patricia Njuguna5, Patrick Munywoki6, Michael Parker7, Sassy Molyneux8,9.
Abstract
BACKGROUND: Benefit sharing in health research has been the focus of international debates for many years, particularly in developing countries. Whilst increasing attention is being given to frameworks that can guide researchers to determine levels of benefits to participants, there is little empirical research from developing countries on the practical application of these frameworks, including in situations of extreme poverty and vulnerability. In addition, the voices of those who often negotiate and face issues related to benefits in practice - frontline researchers and fieldworkers (FWs) - are rarely included in these debates. Against this background, this paper reports on experiences of negotiating research participation and benefits as described by fieldworkers, research participants and researchers in two community based studies.Entities:
Mesh:
Year: 2014 PMID: 25539983 PMCID: PMC4391117 DOI: 10.1186/1472-6939-15-90
Source DB: PubMed Journal: BMC Med Ethics ISSN: 1472-6939 Impact factor: 2.652
Key features of the two community based case studies
|
|
|
|
|---|---|---|
| Study question/objective | Define and quantify who acquires infection from whom in relation to transmission of respiratory syncytial virus (RSV) in households. | Evaluate the efficacy of a ‘promising’ malaria candidate vaccine against malaria disease in infants and children, and across diverse malaria transmission settings in Africa; aimed to address key safety and efficacy information required for vaccine licensure. |
| Study design | Basic science descriptive study. | Double blind (observer blind), randomized, controlled, multi-centre study. |
| Study period | Oct 2009 – June 2010; participant involvement for 6 months. | 2008 – 2013 (later extended to 2015); participant involvement for 34 months. |
| Number of study sites | One site in KEMRI-WT, Kilifi. | Eleven sites in seven African countries. |
| Study area in Kilifi | One location, 15 kms from the Kilifi County Hospital (KCH), within KHDSS. | Three administrative divisions, 30 kms from KCH, 5 locations, in Kilifi County. |
| Composition of study team | A total of 16 team members; | Minimum of 47 staff; |
| • 10 FWs, 2 data entry clerks, one each SFW, clinician, coordinator, PI and senior researcher, | • 36 FWs, 3 SFWs, 3 clinicians, 2 Medical officers, and one each of study coordinator, PI and senior researcher; | |
| • Team also included shared staff (lab technicians, drivers) with other projects. | • Team also included shared staff (data entry clerks, lab technicians, and drivers) with other projects. | |
| Participants | Entire household in a defined geographic locality; household - where members living in the same compound and with a common eating arrangement e.g. share meals made from the same kitchen. HH selected if had an infant born after previous RSV epidemic; and at least one elder sibling. | Children aged 6-12 weeks and 5-17 months at first vaccination; 16,000 children across the 11 sites, a minimum of 6,000 in each of the age category; |
| For Kilifi site, allocated total of 900 children, 600 and 300 in the 5-17 months 6-12 weeks group respectively. |
Study procedures and FW roles in the two case studies
|
|
| |
|---|---|---|
| Study procedures | Follow-up visits at home every 3-4 days; data from each HH member collected at each visit included: | Randomisation to one of three groups |
| • Temperature, | • Experimental malaria vaccine and its booster at 1.5 years | |
| • Nasopharyngeal flocked swab (NFS), | • Experimental malaria vaccine and a different | |
| • Respiratory illness signs and symptoms, | • Booster dose of either Meningitis and | |
| • Respiratory rate taken for all children under 5 years, | • Septicaemia vacci;ne; and | |
| • Three doses of rabies vaccine plus a different booster doses of Meningitis and septicaemia; | ||
|
| ||
| • Oral swab (taken at alternate visits (once-a-week). | • Initial physical examination, medical history, anthropometric tests, temperature. | |
| • Three vaccine doses each a month apart, and | ||
| A demographic and risk assessment questionnaire administered at beginning and end of the study. | • booster dose at 34 months. | |
| • 5 scheduled blood samples over 3 years; each 2.5mls. | ||
| • Monitoring of minor and serious adverse events; immediate post-vaccination and over time. | ||
| • 6 consecutive follow-up visits post-vaccination at home. Monitoring of minor and serious adverse events. | ||
| • Referral to nearest health facility for common illnesses, and to KCH for serious illnesses as advised by attending clinician. | ||
| Fieldworkers roles | FWs Carried out all the study procedures at the households. | FWs Undertook the following roles: |
| • Home follow-up visits to monitor minor and serious adverse events. | ||
| • Where necessary, made referrals to the health facilities. | ||
| • Organised for transport and food for all those attending the health facility | ||
| • On rota at the local healthy facilitate to assist with anthropometric measures, temperature, and keeping of research data records | ||
| • Followed-up research defaulters. |
Anticipated risks and benefits in the two case studies
|
|
| |
|---|---|---|
| Risks | • Mild discomfort during NFS taking. | • Detailed side effects - as is typical of vaccine trials - provided in the study protocol and informed consent, |
| • Time inconveniences. | • Include severe (such as convulsions, diarrhoea) and mild events (e.g. pain, swelling at vaccination site). | |
| Benefits | For |
|
| • Free medical care for all common illnesses (such as diarrhoea, fever regardless of cause, acute respiratory illness etc) during study. | • Free health care for all routine illnesses (e.g. pneumonia, diarrhoea, URTI), vaccine related or otherwise, injuries), throughout the study period (about 3 years), and 1st visit of chronic illnesses (such as sickle cell disease, HIV, epilepsy). This includes: | |
| • Clinical visits to every participating household once a month at home. | • Free referral for specialized treatment where required, all costs at government facilities covered while transport is provided for first visit to non-government facilities; | |
| • Other benefits/token staggered throughout the study period included two chairs to each household, sweets, educational materials and token1 at end of study. | ||
| • All transport to and from the hospital provided by the study team; | ||
| • Meals provided for participant and accompanying parents/guardian for all clinic visits; | ||
|
|
| |
| • Boosting of three health facilities where the study is based; renovation of existing buildings, providing equipment; boosting of health staff, provision of essential drugs, | ||
| • Boosting local health services through provision of drugs, additional clinical staff. | ||
| • Water treatment for all communal water points. | ||
| • Provision of emergency medical aid during cholera epidemic including drugs, staff, referrals. |
1Token given at the end of the study were said to be the study teams appreciation to participants for having persevered until the end of the study. They included educational materials, food items, and clothes to family members.
Explanation in informed consent forms (ICFs) about benefits
| Case Study | Explanation in informed consent forms |
|---|---|
|
|
|
| A vaccine is not yet available to prevent RSV infection but is under development. In order to know which group to target for vaccination in future when that vaccine becomes available, we need to know how the virus is spread within the community. We aim to closely monitor respiratory infections within members of the household in order to understand who transmits the RSV infection to young children. | |
|
| |
| You/your child will benefit from close monitoring for any illness by a nurse during the home visits and will be referred to the health centre for further consultation and treatment where necessary. Medical expenses for outpatient treatment of acute illnesses will be paid for and where applicable transport costs and treatment at the Kilifi District Hospital will be met by KEMRI. These benefits will be applicable during the period of participation in this study only | |
|
|
|
| Malaria is a common and serious disease in young children that results in many deaths. This study is a test of a new vaccine called (name of vaccine*) to see if it can prevent malaria. If the experimental vaccine works, then it might become part of the routine program of immunization in Africa. To date, there is no licensed vaccines to prevent malaria, the experimental malarial vaccine (name) is still being tested because it’s not known how well it will work in preventing malaria. | |
| Even if your child takes part in the study, you must continue to follow the methods you normally use to prevent malaria in your family. Sleeping under an insecticide treated bed net with no holes in it can help protect against malaria. And if your child becomes ill, you should seek medical care as soon as possible. | |
|
| |
| If your child takes part in the study, and receives the first vaccination, he/she will receive medical care from the day of the first dose of vaccine until the completion of the study. This care will include treatment of any symptoms caused by the vaccine or injuries related to the study procedures, as well as treatment for any acute illnesses during the study period and free of charge. Treatment of chronic (long-term) illnesses/injuries unrelated to the study or study procedure will not be paid for by the study. If your child is found to have such illnesses/injuries, he/she will be treated under the existing government services/programs. If your child has a medical problem that cannot be treated at the nearest health centre, we will refer him/her to colleagues at an appropriate clinic. If this were to happen, we will arrange transport for the first visit to see the doctor. All transport to and from the hospital will be provided by the study team so it should not cost you any money to let your child take part in the trial. You will not receive any direct payment just for participating in this study |
*Name of vaccine cannot be disclosed as permission not granted by the pharmaceutical company to do so.
Summary of interview methods and respondents
| Interview type | Respondents |
|---|---|
| In-depth interviews (IDI) | 6 IDIs with RSV-study researchers, two each with PI, Study coordinator, Senior FW |
| 1 IDI with one FW in the Malaria-study | |
| Natural group discussions | 5 Natural (household) group discussions with 16 adults participating in the RSV-study |
| Focus group discussions (FGD) | 3 FGDs with 10 FWs in the RSV-study (one group interviewed twice) |
| 3 FGDs with 26 Field workers in the Malaria-study | |
| 4 FGDs with 24 participants (grouped per gender) in the Malaria-study | |
| 1 FGD with 5 SFW in the Malaria-study |
Box 1: Explanation in informed consent forms (ICFs) about benefits2 Name of vaccine cannot be disclosed as permission not granted by the pharmaceutical company to do so.
Questionnaire guides used in interviews with participants and fieldworkers in RSV-study
| Group discussion with participants in case studies | ||
|---|---|---|
|
| ||
| 1 | When did you join the study (RSV-study)? How did you come to know about the study? | |
| 2 | Since the study involved the whole family: | |
| • | how did you know about the study (who informed you about the study, when and where) | |
| • | How did you make the decision to participate? (who was consulted in the family before the decision to participate was made, why were they consulted | |
| • | Who was not consulted and why not? ( | |
| • | What contributed to your decision to join the study? | |
| 3 | How long did you participate in the study for (a short while then dropped, continued to end of study etc.); | |
| • | What made you participate to the end of the study? | |
| • | Did any of the HH members change their decisions as the study continued? Why? How did you handle this? (probe: how they communicated about their decision) | |
| • | Did any of the HH members drop out of the study and why? What did other HH members feel about this decision? What was done about the decision (e.g. accepted by the study team, talked out of decision) | |
| 4 | What were some of the most difficult/challenges that you faced while participating in the study (prompt for: | |
| • | Study related e.g. procedures, fears around nasal swabbing (e.g. why they were afraid of the nasal swabs), any other | |
| • | Study benefits and who received these, and how they felt about them | |
| • | HH challenges around continued participation e.g. time involvement, school going children, | |
| • | Study team related issues e.g. frequency of FW visits | |
| • | Dealing with non-participating community members. | |
| 5 | How were these challenges overcome? – by who, | |
| • | any consultations with the HH members, | |
| • | What was the FWs/study team involvement in resolution (prompt for whether FWs took extra steps to ensure the issues/challenges were resolved) etc. | |
|
| ||
| 6 | Now that the study has ended, | |
| • | What are your views/opinions about the study? | |
| • | What are your views about the FWs and the study team (i.e. how did they handle any of the questions and challenges that participants faced). | |
| • | Did you face any issues with community members who were not participating? What issues, how did you handle them? Why do you think those issues arose? | |
|
| ||
| 7 | In future if invited to participate in a KEMRI research, would you participate, why/why not? What would you consider in making that decision? | |
| 8 | Any recommendations? | |
|
| ||
|
| ||
| 1 | Since the last time we talked, did any of the study procedures change? Did any of your FW roles change, if yes, why and in what ways; what were the implications of such changes? | |
|
| ||
| 2 | The HH study ended two weeks ago, what activities are you currently involved in? | |
| 3 | The last time we discussed, you were not very sure that the study will progress to end. Now that it has ended: | |
| • | How do you feel the study performed? Was it a success? In what ways? Did it fail in some ways? | |
| • | Overall what are your views about the study? | |
| 4 | The study overall has been a success in retaining participants to the end; | |
| • | What contributed to such success? (Prompt for what changed in the study so it progressed to the end successfully? How study benefits contributed? How relationship with FWs and study team/researchers contributed) | |
| • | What do you think was your contribution in making this study a success? | |
| • | Did you have HH that withdrew from the study? How many and how did you handle this? | |
| • | Did you have HH that wanted to withdraw and did not? How many and what happened till they did not withdraw? | |
| • | Did you have HH that wanted to re-join the study? How did you handle this? | |
| • | Overall what worked well in this study? | |
| • | Overall what did not work so well, how was this addressed (e.g. FW support system etc.) | |
| 5 | On reflections, what was the most challenging situation you faced in this study? How was it handled? What was your role in resolving it? What are your opinions about the way it was resolved? | |
| 6 | Performance chart for each FW was introduced as the study progressed, what are your views about it? Is this something that other teams can use? | |
| 7 | Now that the study has come to an end; how do you feel about the end of the study? | |
| • | How do you relate with the participants? | |
| • | What are your perceptions on how the participants feel about the study, and the study team? | |
| • | How do non-participants feel about those who participated? | |
| 8 | How was end of the study communicated, a) to you b) to the participants c) to the community; what are your views about this process of communication. | |
| 9 | What are your plans for the future? | |
| 10 | Any recommendations | |